Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Andreas Busch

- PMLiVE

Shire claims FDA approval for slow-cooked ADHD drug

Mydayis will reach the US market in the third quarter of the year

Bayer symbol

Bayer wins FDA approval for MS electronic autoinjector and app

US regulator gives green light to Betaconnect and myBETA app

Bayer symbol

Bayer’s lymphoma drug copanlisib gets speedy FDA review

The PI3K inhibitor will be assessed for relapsed or refractory follicular lymphoma

- PMLiVE

Shire licences Parion dry eye drug in $535m deal

Bolsters the Irish group's ophthalmic portfolio

Bayer symbol

FDA OK for Stivarga ends decade-long drought in liver cancer

Bayer's medicine wins US approval to treat hepatocellular carcinoma

Shire Basingstoke

Shire finally bags EU approval for rare disease drug Natpar

Becomes first licenced treatment for hypoparathyroidism in Europe

National Institute for Health and Care Excellence NICE logo

NICE knocks-back Shire’s pancreatic cancer drug Onivyde

Final guidance rules it's not a cost-effective use of NHS resources

Choices, choices…

Not all innovative business models are equal

- PMLiVE

Xarelto beats aspirin for recurrent blood clots

Trial shows the NOAC reduces the risk of blood clots by 74%

- PMLiVE

Bayer: Post-truth politics severely handicaps innovation

And firm also voices its concerns over Brexit

- PMLiVE

J&J gets CHMP backing for broader Darzalex use

Recommendation for earlier-stage approval could see multiple myeloma drug reach blockbuster sales

- PMLiVE

Xarelto and Eylea continue to dominate Bayer’s pharma sales

And firm looks for turnaround in 2017 from Stivarga

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links